LENZ Therapeutics, Inc. (LENZ) Form 8-K — Aug 11, 2026
LENZ Therapeutics reported Q2 2026 total revenue of $5.5 million, combining $1.7 million in net product sales on roughly 27,000 packs of VIZZ with $3.8 million in license revenue. Product sales grew 9% sequentially over Q1 2026, while the net loss widened to $31.9 million, or $1.02 per share, from $14.9 million, or $0.53 per share, a year ago as launch spending ramped. Early launch metrics validated the persistence thesis: over 60% of ePharmacy patients have bought more than one monthly pack with early cohorts tracking to about five packs annually, and more than 13,000 unique prescribers have written VIZZ since launch, roughly 75% of them multiple times.
Key figures
- Revenue
- 5486000
- Total Assets
- 236596000
- Cash Position
- 220000000
- Rnd q2 usd
- 0
- Sga h1 usd
- 84338000
- Sga q2 usd
- 39378000
- Packs sold h1
- 52000
- Packs sold q2
- 27000
- Net loss h1 usd
- 73406000
- Total liabilities usd
- 17334000
- License revenue q2 usd
- 3750000
- Weighted avg shares q2
- 31374311
- Stockholders equity usd
- 219262000
- Product sales net h1 usd
- 3387000
- Product sales net q2 usd
- 1736000
- Prior year q2 net loss usd
- 14912000
- Product sales qoq growth pct
- 9
- Thea remaining milestones usd
- 65000000
- Unique prescribers since launch
- over 13,000
- Everest remaining milestones usd
- 85000000
- Ex us regulatory filings to date
- 9
- Thea milestone recognized q2 usd
- 2500000
- Epharmacy patients multi pack pct
- over 60%
- Everest sublicense revenue q2 usd
- 1250000
- Projected annual packs per patient
- 5
- Prescribers with multiple scripts pct
- 75
Price after filing
Close on the filing date to close N calendar days later (from $5.36). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.